Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV

CONCLUSION: In our study patients had a high persistence. Patients on DTG/3TC treatment were more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF was tolerability/toxicity.PMID:38448360 | DOI:10.1016/j.farma.2024.02.002

Source: Farmacia Hospitalaria - March 6, 2024 Category: Drugs & Pharmacology Authors: Lorena Mart ín-Zaragoza Javier S ánchez-Rubio-Ferrández Alberto Onteniente-Gonz ález Marcos G ómez-Bermejo Sergio Julio Rodr íguez-Álvarez Alfonso Monereo-Alonso Teresa Molina-Garc ía Source Type: research